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A B S T R A C T
(6R)-5,6,7,8-Tetrahydro-L-biopterin (BH4) availability regulates nitric oxide and superoxide formation
by endothelial nitric oxide synthase (eNOS). At low BH4 or low BH4 to 7,8-dihydrobiopterin (BH2) ratios
the enzyme becomes uncoupled and generates superoxide at the expense of NO. We studied the effects
of exogenously added BH2 on intracellular BH4/BH2 ratios and eNOS activity in different types of
endothelial cells. Incubation of porcine aortic endothelial cells with BH2 increased BH4/BH2 ratios from
8.4 (controls) and 0.5 (BH4-depleted cells) up to 20, demonstrating efﬁcient reduction of BH2.
Uncoupled eNOS activity observed in BH4-depleted cells was prevented by preincubation with BH2.
Recycling of BH4 was much less efﬁcient in human endothelial cells isolated from umbilical veins or
derived from dermal microvessels (HMEC-1 cells), which exhibited eNOS uncoupling and low BH4/BH2
ratios under basal conditions and responded to exogenous BH2 with only moderate increases in BH4/
BH2 ratios. The kinetics of dihydrofolate reductase-catalyzed BH4 recycling in endothelial cytosols
showed that the apparent BH2 afﬁnity of the enzyme was 50- to 300-fold higher in porcine than in
human cell preparations. Thus, the differential regulation of eNOS uncoupling in different types of
endothelial cells may be explained by striking differences in the apparent BH2 afﬁnity of dihydrofolate
reductase.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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jo u rn al h om epag e: ww w.els evier .c o m/lo cat e/bio c hem p har m1. Introduction
The pterin derivative tetrahydrobiopterin (BH4) is essential for
endothelial NO formation. It binds to endothelial nitric oxide
synthase (eNOS) in immediate vicinity of the heme and promotes
the transfer of electrons from the reductase domain to the heme
group, where oxygen is reduced and incorporated into the
guanidine group of the substrate, L-arginine. At subsaturating
concentrations of BH4, autoxidation of the ferrous-oxy and
ferrous-superoxy complexes results in release of superoxide anionAbbreviations: amino-BH4, 4-amino-(6R)-5,6,7,8-tetrahydro-L-biopterin; BAECs,
bovine aortic endothelial cells; BH2, 7,8-dihydro-L-biopterin; BH4, (6R)-5,6,7,8-
tetrahydro-L-biopterin; cGMP, 30 ,50-cyclic guanosine monophosphate; DAHP, 2,4-
diamino-6-hydroxypyrimidine; DEA/NO, 2,2-diethyl-1-nitroso-oxyhdrazine; DHF,
7,8-dihydrofolate; DHFR, dihydrofolate reductase; eNOS, endothelial nitric oxide
synthase; GTPCH, guanosine triphosphate cyclohydrolase I; HUVECs, human
umbilical vein endothelial cells; L-NMA, NG-methyl-L-arginine; L-NNA, NG-nitro-L-
arginine; NO, nitric oxide; PAECs, porcine aortic endothelial cells; ROS, reactive
oxygen species; THF, 5,6,7,8-tetrahydrofolate.
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http://dx.doi.org/10.1016/j.bcp.2014.05.010
0006-2952/ 2014 The Authors. Published by Elsevier Inc. This is an open access article unand hydrogen peroxide at the expense of the L-citrulline and NO
[1]. This phenomenon, referred to as eNOS uncoupling, has been
implicated in endothelial dysfunction associated with a variety of
cardiovascular diseases including atherosclerosis, hypertension
and diabetes [2–4]. Over the past several years, evidence has
accumulated that in addition to BH4 levels, the intracellular ratio
of BH4 vs. its oxidation product, dihydrobiopterin (BH2), also
determines endothelial function. BH2 competes with BH4 for
binding to eNOS but does no provide electrons for reductive
oxygen activation [5–7]. Accordingly, eNOS uncouples at low BH4/
BH2 ratios even at sufﬁciently high BH4 concentrations.
Intracellular levels of BH4 and BH4/BH2 ratios are controlled by
de novo and salvage pathways [8,9]. Guanosine triphosphate
cyclohydrolase I (GTPCH) is the ﬁrst and rate-limiting enzyme in
the de novo biosynthetic pathway. It catalyzes the hydrolysis of
GTP to 7,8-dihydroneopterin triphosphate, which is then con-
verted to BH4 by the consecutive action of 6-pyruvoyltetrahy-
dropterin synthase and sepiapterin reductase. GTPCH activity, and
thus de novo synthesis of BH4 is primarily regulated at the
transcriptional level by several cytokines and hormones, which
either up- or down-regulate GTPCH expression levels, as well as byder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
K. Schmidt et al. / Biochemical Pharmacology 90 (2014) 246–253 247posttranslational modiﬁcations and by interaction of GTPCH with
its feedback regulatory protein. Moreover, GTPCH activity can be
efﬁciently inhibited by 2,4-diamino-6-hydroxypyrimidine (DAHP),
a pharmacological tool used for the depletion of cellular BH4.
In addition to its de novo biosynthesis, BH4 can be enzymati-
cally regenerated from its oxidation products quinonoid 6,7-[8H]-
dihydrobiopterin and 7,8-dihydrobiopterin (BH2) by dihydropter-
idine reductase and dihydrofolate reductase (DHFR), respectively.
While the role of dihydropteridine reductase in maintaining
endothelial function is unclear (the quinonoid 6,7-[8H]-dihydro-
biopterin rearranges non-enzymatically to BH2, which is then
reduced to BH4 by DHFR), inhibition or knockout of DHFR in
cultured endothelial cells has been shown to reduce intracellular
BH4:BH2 ratios and NO/L-citrulline formation [10–12], hinting at a
critical role of DHFR in regulating eNOS uncoupling. More recently
the results obtained with cultured cells have been corroborated by
in vivo experiments showing that treatment of BH4-deﬁcient mice
with the DHFR inhibitor methotrexate induces reduction of
BH4:BH2 ratios und eNOS uncoupling in lung tissue [13].
As demonstrated with human aortic endothelial cells, bovine
aortic endothelial cells (BAECs) and the murine endothelial cell line
sEnd.1, the capacity of DHFR in reducing BH2 to BH4 is apparently
rather low, as the cells respond to extracellular BH2 with a
substantial increase in intracellular BH2, diminished NO and
enhanced superoxide formation even if DHFR is not inhibited or
knocked out [5,12,14]. These ﬁndings showing that supplementa-
tion of cells with BH2 induces eNOS uncoupling were in striking
contrast to our preliminary observation that BH2 restores eNOS
function in BH4-depleted porcine aortic endothelial cells (PAECs).
The present study was aimed at clarifying whether cell type-
speciﬁc differences in BH2-to-BH4 reduction may account for the
differential effects of BH2 supplementation on eNOS function.
2. Materials and methods
2.1. Materials
L-[2,3-3H]Arginine hydrochloride (1.5–2.2 TBq/mmol) was
from American Radiolabeled Chemicals, Inc. (St. Louis, MO, USA)
and puriﬁed as described earlier [15]. DEA/NO was obtained from
Alexis Corporation (Lausen, Switzerland) and dissolved and diluted
in 10 mM NaOH. Dihydroethidium was from Calbiochem –
Merck4Biosciences (Darmstadt, Germany) and dissolved in DMSO.
BH4, BH2 and amino-BH4 were from Schircks Laboratories (Jona,
Switzerland). Antibiotics and fetal calf serum were purchased from
PAA Laboratories (Linz, Austria). Culture media and other
chemicals were from Sigma–Aldrich (Vienna, Austria).
2.2. Culture and treatment of endothelial cells
Porcine aortic endothelial cells (PAECs) were isolated as
described [16] and cultured at 37 8C, 5% CO2, in Dulbecco’s
modiﬁed Eagle’s medium, supplemented with 10% (v/v) heat-
inactivated fetal calf serum, 100 U/ml penicillin, 0.1 mg/ml
streptomycin, and 1.25 mg/ml amphotericin B. Human umbilical
vein endothelial cells (HUVECs) were isolated as described [17] and
cultured in Medium 199, supplemented with 15% (v/v) heat-
inactivated fetal calf serum, 100 U/ml penicillin, 0.1 mg/ml
streptomycin, 1.25 mg/ml amphotericin B, 2 mM L-glutamine,
5000 U/ml heparin, and 10 mg/ml endothelial cell growth factor.
The human microvascular endothelial cell line, HMEC-1 [18] was
kindly provided by F.J. Candal (Centers for Disease Control, Atlanta,
GA, USA) and was maintained in medium MCDB131 supplemented
with 15% (v/v) heat-inactivated fetal calf serum, 100 U/ml
penicillin, 0.1 mg/ml streptomycin, 1.25 mg/ml amphotericin B,
10 ng/ml epidermal growth factor, and 1 mg/ml hydrocortisone.Where indicated, cells were pretreated in culture medium
containing DAHP, aminopterin and/or pteridines.
2.3. Determination of endothelial L-[3H]citrulline formation
Intracellular conversion of L-[3H]arginine into L-[3H]citrulline
was measured as previously described [19]. Brieﬂy, cells grown in
6-well plates were washed and equilibrated for 15 min at 37 8C in
50 mM Tris buffer, pH 7.4, containing 100 mM NaCl, 5 mM KCl,
1 mM MgCl2 and 2.5 mM CaCl2 (incubation buffer). Reactions were
started by addition of L-[2,3-3H]arginine (106 dpm) and A23187
(1 mM) and terminated after 10 min by washing the cells with
chilled incubation buffer. Subsequent to lysis of the cells with
0.01 N HCl, an aliquot was removed for the determination of
incorporated radioactivity. To the remaining sample, 200 mM
sodium acetate buffer (pH 13.0) containing 10 mM L-citrulline was
added (ﬁnal pH 5.0), and L-[3H]citrulline separated from L-
[3H]arginine by cation exchange chromatography [19].
2.4. Determination of endothelial cGMP formation
Accumulation of intracellular cGMP was determined as
previously described [19]. Brieﬂy, cells grown in 24-well plates
were washed and preincubated for 15 min at 37 8C in incubation
buffer (see above), additionally containing 1 mM 3-isobutyl-1-
methylxanthine and 1 mM indomethacin. Reactions were started
by addition of A23187 (1 mM) and terminated after 4 min by
removal of the incubation medium and addition of 0.01 N HCl.
Within 1 h, intracellular cGMP was completely released into the
supernatant and measured by radioimmunoassay.
2.5. Determination of endothelial reactive oxygen species (ROS)
formation
Cells grown on glass coverslips were incubated for 10 min at
37 8C in incubation buffer containing 10 mM dihydroethidium,
washed and incubated for further 30 min with buffer containing
1 mM A23187. Alternatively, cells were incubated for 4 h in phenol
red free culture medium containing 10 mM dihydroethidium and,
where indicated, stimulated with 1 mM A23187 1 h prior to the
end of incubation. The latter method allowed a more reliable
measurement of basal ROS formation and was used for the
experiments shown in Fig. 5. Subsequent to incubation, cells were
washed with incubation buffer and ﬂuorescence imaging was
performed at room temperature using a Zeiss Axiovert 200 setup,
equipped with a xenon lamp, polychromator, Chroma ﬁlters
(exciter: HQ546/12; emitter: HQ605/75; beamsplitter: Q560lp)
and a CoolSNAP fx-HQ CCD-camera (Visitron Systems GmbH,
Puchheim, Germany). The microscopic ﬁelds were selected
randomly and the exposure time was 5 s for each image. Routinely,
3 images were taken and at least 50 cells/coverslip were analyzed
using the Meta Imaging Series 5.0 software from Universal Imaging
Corporation (Downingtown, PA, USA) or the open source image
analysis program, ImageJ (http://imagej.nih.gov/ij/). Values were
corrected for background ﬂuorescence measured in cell-free areas.
2.6. Determination of BH4, BH2 and biopterin levels
Intracellular levels of pteridines were quantiﬁed by HPLC
analysis using a method adapted from Fukushima and Nixon [20]
as described previously [21]. Brieﬂy, cells grown in petri dishes
(diameter 90 mm) were harvested (5  106 per petri dish),
washed, and resuspended in either 0.1 ml of PBS containing 1 mM
DTT (for quantifying biopterin), 0.1 ml of alkaline oxidant solution
(0.02 M KI/I2 in 0.1 M NaOH; for quantifying biopterin plus BH2), or
0.1 ml of acidic oxidant solution (0.02 M KI/I2 in 0.1 M HCl; for
Fig. 1. Effect of pteridine supplementation on eNOS activity in BH4-depleted PAECs.
PAECs were pretreated for 24 h with culture medium in the absence (Ctrl) or the
presence of 10 mM DAHP. Where indicated, pteridines were added to the medium 1
h prior to the end of the DAHP treatment. Then, cells were washed and L-arginine to
L-citrulline conversion (A) or cGMP formation (B) determined as described in
Section 2. Data are mean values  S.E.M. of 3–5 independent experiments (**p < 0.01,
*p < 0.05 compared with untreated control).
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the cells by sonication, 20-ml aliquots were removed for protein
determination, and the remaining samples were incubated for 1 h
in the dark at room temperature. Then, samples oxidized under
alkaline or acidic conditions were mixed with 10 ml of 1 M HCl or
water, respectively, and centrifuged. The resulting supernatants
were mixed with 10 ml of 0.2 M ascorbic acid and neutralized by
addition of 1 M phosphate buffer, pH 8.0. Non-oxidized samples
were mixed with 30 ml of water and centrifuged. For HPLC analysis,
samples were loaded on a LiChrospher 100 RP 18 HPLC column,
5 mm particle size (Merck, Darmstadt, Germany) and eluted with
20 mM NaH2PO4, pH 3, containing 5% methanol at a ﬂow rate of
1 ml/min. Biopterin was quantiﬁed with a ﬂuorescence detector at
excitation and emission wavelengths of 350 and 440 nm,
respectively, by interpolation in calibration curves that were
established daily with authentic BH2 (3–300 nM) oxidized under
acidic conditions. BH4 and BH2 levels were calculated based on the
amount of biopterin measured after oxidation in acid (biopter-
in + BH2 + BH4), after oxidation in base (biopterin + BH2), or in
non-oxidized samples (biopterin). In accordance with literature
data [20], 90.6  6.5% of BH2 and 100.7  3.5% of BH4 were
recovered as biopterin after oxidation in acid (mean values  SD,
n = 10). In base, the recovery of BH2 was 86.7  7.4%, whereas only
1.2  0.2% of BH4 was oxidized to biopterin under this condition.
2.7. Determination of DHFR activity in cell cytosols and PD10 eluates
Cells grown in petri dishes were harvested, washed with 10 mM
triethanolamine/HCl buffer, pH 7.4, containing 10 mM DTT and
0.5 mM EDTA and lysed by three cycles of freeze/thawing.
Cytosolic fractions were obtained by centrifugation at 100,000 g
for 1 h and, where indicated, passed over a Sephadex G 25 column
(PD10, GE Healthcare Europe GmbH, Vienna, Austria). DHFR
activity was measured by a method adapted from published
procedures [22,23]. Brieﬂy, cytosolic fractions or PD10 eluates
containing 5–20 mg of protein were incubated at 37 8C in a total
volume of 0.1 ml of 100 mM phosphate buffer, pH 7.4, containing
1 mM DTT, 20 mM ascorbate, 1 mM EDTA, 50 mM NADPH and
either DHF or BH2 at concentrations indicated. After 10 min,
reactions were terminated by addition of 10 ml trichloroacetic acid
(2 N) and precipitates removed by centrifugation (5 min at
10,000  g). When DHF was used as substrate, samples were
mixed with 10 ml of stabilization solution (containing 1 M
ascorbate and 100 mM DTT), loaded on a LiChrospher 100 RP 18
HPLC column, 5 mm particle size (Merck, Darmstadt, Germany)
and eluted with 5 mM KH2PO4, pH 2.3, containing 7% acetonitrile at
a ﬂow rate of 1 ml/min. THF was quantiﬁed with a ﬂuorescence
detector at excitation and emission wavelengths of 295 and
365 nm, respectively, by interpolation in calibration curves that
were established daily with authentic THF (0.1–5 mM).
When BH2 was used as substrate, samples were mixed with
100 ml of alkaline oxidant solution (0.04 M KI/I2 in 0.4 M NaOH)
and incubated for 1 h in the dark at room temperature. Then,
samples were mixed with 26 ml of 1 M HCl and centrifuged. The
resulting supernatants were mixed with 26 ml of 0.2 M ascorbic
acid and neutralized by addition of 1 M phosphate buffer, pH 8.0.
For HPLC analysis, samples were loaded on a Nucleosil 100-10 SA
HPLC column (Macheray-Nagel, Germany) and eluted with 50 mM
NaH2PO4, pH 3 at a ﬂow rate of 1.5 ml/min. BH4 was quantiﬁed as
pterin with a ﬂuorescence detector at excitation and emission
wavelengths of 350 and 440 nm, respectively, by interpolation in
calibration curves that were established daily with authentic BH4
(0.2–2 mM) oxidized under the same conditions. DHFR acitivty
data were corrected for non-enzymatic BH2/DHF reduction
measured in heat-inactivated cell cytosols. Enzyme kinetic
parameters were calculated by nonlinear regression to theMichaelis–Menten equation by using KaleidaGraph (Synergy
Software). Speciﬁcally, Km and Vmax were derived from ﬁts to
the equation f = a  [S]/(b + [S]), with ﬁtting parameters a = Vmax
and b = Km, whereas Vmax/Km was obtained by ﬁtting the same
result to the equation f = a  [S]/(1 + [S]/b), with ﬁtting parameters
a = Vmax/Km and b = Km.
2.8. Statistical analysis
Results are expressed as the mean  standard error of the mean
(S.E.M.). Statistical differences within groups were evaluated by one-
factor analysis of variance (ANOVA), followed by Fisher’s LSD test.
Analyses were performed with KaleidaGraph (Synergy Software).
3. Results
3.1. Effect of pteridine supplementation on eNOS activity in BH4-
depleted PAECs
The activity of eNOS in PAECs was monitored by measuring the
conversion of 3H-arginine to 3H-citrulline (Fig. 1A) and accumula-
tion of cGMP (Fig. 1B) in the presence of a maximally active
concentration of the Ca2+ ionophore A23187 (1 mM). As shown in
panel A, inhibition of de novo biosynthesis of BH4 by preincubating
the cells for 24 h with the GTP cyclohydrolase inhibitor DAHP
(10 mM) diminished L-[3H]citrulline formation from 106  9 to
Table 1
Effect of pteridine supplementation on intracellular BH2/BH4 levels in PAECs.
Treatment BH4 (pmol/
mg protein)
BH2 (pmol/
mg protein)
BH4/BH2
(ratio)
None 6.7  0.8 0.8  0.3 8.4
DAHP (10 mM) 0.1  0.1** 0.2  0.1 0.5
+10 mM BH2 4.3  1.4 0.2  0.1 21.5
+0.1 mM BH2 28.6  6.1** 1.4  0.4 20.4
+10 mM BH4 1.3  0.9 0.4  0.2 3.3
+0.1 mM BH4 8.7  1.9 0.3  0.2 29.0
BH2 (10 mM) 11.9  2.0 0.6  0.1 19.8
BH2 (0.1 mM) 49.0  7.7** 2.7  0.8 18.1
BH4 (10 mM) 7.1  1.9 0.4  0.2 17.8
BH4 (0.1 mM) 12.1  4.0 0.7  0.1 17.3
Aminopterin (0.1 mM) 5.3  0.6 3.5  1.1 1.5
+10 mM BH2 7.0  1.5 6.7  2.8 1.0
+0.1 mM BH2 13.3  2.6 30.8  8.4** 0.4
For pteridine supplementation, PAECs were incubated with either BH2 or BH4 for
1 h in culture medium, and intracellular BH2/BH4 levels were measured as
described in Section 2. Where indicated, experiments were performed with cells
that had been pretreated with DAHP (24 h) or aminopterin (30 min). Data are mean
values  S.E.M. of 4–6 independent experiments.
** p < 0.01 compared with untreated control.
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1 mM) was added to the culture medium 1 h prior to the end of
the DAHP treatment, L-[3H]citrulline formation was increased in a
concentration-dependent manner and completely restored with
0.1 mM of BH4 (102  11 fmol min1 mg1). An even more pro-
nounced effect was observed with BH2, which fully restored L-
[3H]citrulline formation at 10 mM. For comparison, we also
performed experiments with the 4-amino analog of BH4, a pterin
antagonist of NOS [19,24,25]. As expected, a 1-h incubation of DAHP-
treated cells with the 4-amino derivative (ﬁnal concentration 1 mM–
1 mM) further reduced L-[3H]citrulline formation down to basal levels
(11  2 fmol min1 mg1).
In addition to its effect on arginine-to-citrulline conversion,
pretreatment of the cells with DAHP reduced A23187-induced
cGMP accumulation to 41.9  6.8% (Fig. 1B). Interestingly, addition
of BH4 or BH2 not only antagonized the inhibitory effect of DAHP but
also increased cGMP accumulation up to 185  15.4 and 186  18.8%,
respectively. In view of these intriguing results we also measured
cGMP accumulation in response to a maximally active concentration
of DEA/NO (1 mM) and observed that the effect of the NO donor was
also increased 2-fold upon preincubation of the cells with DAHP
(data not shown). These ﬁndings suggest that DAHP (presumably via
inhibiting endothelial NO production) induces a sensitization of the
cGMP response, a phenomenon that might be related to the NO
supersensitivity of blood vessels treated with NO synthase inhibitors
[26].
3.2. Effect of pteridine supplementation on ROS formation in BH4-
depleted PAECs
To test whether the inhibition of L-citrulline/cGMP formation by
DAHP was indeed due to eNOS uncoupling, we measured A23187-
induced reactive oxygen species (ROS) formation by single cell
microscopy using dihydroethidium as ﬂuorescence dye. As shown
in Fig. 2, preincubation of PAECs with DAHP increased the
ﬂuorescence signal from 169  21 to 320  20 AU, and the effect
was prevented by BH4 (149  21 AU) and by BH2 (141  10 AU).
Reduction of DAHP-induced ﬂuorescence by L-NNA (170  16 AU) but
not by L-NMA (315  148 AU), which has no effect on uncoupled
NADPH oxidation by puriﬁed eNOS [27], strongly suggests that the
signal reﬂects eNOS-catalyzed superoxide formation.Fig. 2. Effect of pteridine supplementation on ROS formation in BH4-depleted
PAECs. PAECs grown on glass coverslips were pretreated for 24 h with culture
medium in the absence (Ctrl) or the presence of 10 mM DAHP. Where indicated,
BH4 or BH2 (ﬁnal concentration 0.1 mM) was added to the medium 1 h prior to the
end of the DAHP treatment. Then, cells were incubated with dihydroethidium
(10 mM, 10 min) and stimulated for 30 min with A23187 (1 mM) in the absence and
the presence of L-NNA or L-NMA (0.3 mM, each). ROS formation was quantitated by
ﬂuorescence imaging as described in Section 2. Data are mean values  S.E.M. of 3–5
independent experiments (**p < 0.01 compared with untreated control).3.3. Effect of pteridine supplementation on intracellular BH2/BH4
levels in PAECs
The observation that both BH4 and BH2 restored eNOS function
suggests that BH2 is reduced efﬁciently to BH4 by PAECs, and this
was conﬁrmed by determination of cellular BH4/BH2 levels. As
shown in Table 1, preincubation of the cells with DAHP markedly
reduced the intracellular levels of both reduced biopterins. When
cells were subsequently incubated with 10 mM BH2, intracellular
BH2 remained unchanged (0.2  0.1 pmol/mg), whereas BH4 was
almost completely restored (from 0.1  0.1 to 4.3  1.4 pmol/mg as
compared to 6.7  0.8 pmol/mg in untreated cells). Similarly,
incubation with 0.1 mM BH2 primarily evoked an increase in
intracellular BH4 (28.6  6.1 pmol/mg protein), whereas BH2 was
barely affected (1.4  0.4 pmol/mg protein). Incubation of DAHP-
treated cells with BH4 also led to increased intracellular BH4, but the
effect was signiﬁcantly less pronounced than that induced by BH2
(e.g. 8.7  1.9 and 28.6  6.1 pmol BH4/mg with 0.1 mM BH4 and
0.1 mM BH2, respectively). Similar results were obtained with cells
that had not been pre-treated with DAHP. Incubation with BH2
markedly elevated intracellular BH4 without affecting BH2 levels, and
application of BH2 was more effective in increasing intracellular BH4
than application of BH4 itself, presumably due to faster cellular
uptake of BH2 [28]. To test for a role of DHFR in BH2 reduction, cells
were supplemented with BH2 in the presence of the DHFR inhibitor
aminopterin. As shown in Table 1, aminopterin caused a pronounced
shift from BH4 to BH2, indicating that DHFR is essential for BH4
recycling in PAECs.
3.4. Effect of pteridine supplementation on eNOS activity in untreated
PAECs
To ﬁnd out how eNOS activity is modulated by the various
intracellular BH4 and BH2 levels, we studied the effects of BH4,
BH2 and aminopterin on citrulline and cGMP formation in PAECs
under control conditions, i.e. in cells that had not been pre-treated
with DAHP. As shown in Fig. 3, neither L-[3H]citrulline formation
(panel A) nor cGMP accumulation (panel B) were signiﬁcantly
affected by exogenously added BH4 or BH2, suggesting that the
basal level of 6.7  0.8 pmol BH4/mg protein (see Table 1) is
sufﬁcient for eNOS saturation. Aminopterin (0.1 mM), which in-
creased BH2 levels from 0.8  0.3 to 3.5  1.1 pmol/mg and reduced
Fig. 3. Effect of pteridine supplementation on eNOS activity in PAECs.
PAECs were pretreated for 1 h with culture medium in the absence or the presence
of BH4 or BH2. Where indicated, aminopterin (ﬁnal concentration 0.1 mM) was
added to the medium 30 min prior to addition of BH2. Then, cells were washed and
L-arginine to L-citrulline conversion (A) or cGMP formation (B) determined as
described in Section 2. Data are mean values  S.E.M. of 3–5 independent
experiments (**p < 0.01, *p < 0.05 compared with untreated control).
Table 2
Effect of pteridine supplementation on intracellular BH2/BH4 levels in HMEC-1
cells and HUVECs.
BH4 (pmol/
mg protein)
BH2 (pmol/
mg protein)
BH4/BH2
(ratio)
HMEC-1 cells
None 0.7  0.3 0.5  0.2 1.4
+1 mM BH2 1.5  0.3 0.4  0.2 3.8
+10 mM BH2 8.4  0.6** 1.1  0.4 7.6
+0.1 mM BH2 101.8  6.9** 15.3  6.1** 6.7
Aminopterin (0.1 mM) 0.4  0.3 1.1  0.3 0.36
+1 mM BH2 0.4  0.2 1.6  0.4 0.25
+10 mM BH2 1.1  0.6 9.4  0.7** 0.12
+0.1 mM BH2 2.5  1.4 90.1  1.6** 0.03
HUVECs
None 0.3  0.2 0.4  0.1 0.75
+1 mM BH2 0.8  0.4 0.8  0.6 1.00
+10 mM BH2 5.4 + 0.7* 2.9  0.5* 1.86
+0.1 mM BH2 56.7  4.8** 29.9  4.5** 1.90
Aminopterin (0.1 mM) 0.4  0.2 1.2  0.8 0.33
+1 mM BH2 0.5  0.4 3.6  0.9 0.14
+10 mM BH2 1.7  0.6 13.9  0.6 0.12
+0.1 mM BH2 3.2  1.6 71.5  0.5 0.04
For pteridine supplementation, cells were incubated with either BH2 or BH4 for 1 h
in culture medium, and intracellular BH2/BH4 levels were measured as described in
Section 2. Where indicated, experiments were performed with cells that had been
pretreated for 30 min with aminopterin. Data are mean values  S.E.M. of 4–6
independent experiments.
* p < 0.05 compared with untreated control.
** p < 0.01 compared with untreated control.
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reduced L-L-[3H]citrulline formation and cGMP accumulation in the
presence of BH2 (to 70–80% of controls at 0.1 mM). These results
indicate that inhibition of DHFR results in intracellular accumulation
of BH2, which competes with endogenous BH4 for eNOS binding.
3.5. Comparison with other endothelial cells
In contrast to our observations with PAECs, endothelial cells from
other sources (bovine and human aorta as well as the murine sEnd.1
cell line) have been reported to respond to BH2 supplementation
with a pronounced increase in intracellular BH2 levels [5,12,14],
suggesting that the efﬁciency of BH4 recycling varies among
different types of endothelial cells. To address this issue we
performed experiments with the human microvascular endothelial
cell line HMEC-1 and cells isolated from human umbilical veins
(HUVECs). As shown in Table 2, HMEC-1 cells exhibited rather low
levels of BH4 (0.7 pmol/mg) and a BH4/BH2 ratio as low as 1.4.
Incubation of the cells with BH2 evoked primarily an increase in
intracellular BH4, and upon treatment with 10 mM BH2, both BH4
levels and the BH4/BH2 ratio was comparable to that of untreated
PAECs (see Table 1). As expected from the low intracellular biopterin
levels, eNOS was signiﬁcantly less active in HMEC-1 cells than in
PAECs, but the formation of L-[3H]citrulline was increased by BH2
supplementation (from 67  5 to a maximum of101  10 fmol min1 mg1 with 10 mM BH2) (Fig. 4A). Incubation
with 0.1 mM aminopterin in the absence of BH2 slightly decreased L-
[3H]citrulline formation to 51  4 fmol min1 mg1. The effect of the
DHFR inhibitor was enhanced by co-incubation with BH2, resulting in
virtually complete eNOS inhibition at 1 mM BH2. Table 2 shows that
the effect of BH2 correlated with a decrease in the BH4/BH2 ratio from
0.36 to 0.03.
In untreated HUVECs, basal levels of BH4 (0.3  0.2 pmol/mg,
Table 2) and L-[3H]citrulline formation (36  2 fmol min1 mg1,
Fig. 4B) were even lower than in HMEC-1 cells. Moreover, HUVECs
responded to supplementation with BH2 not only with an increase in
BH4 levels but also in a substantial elevation of intracellular BH2,
leading to BH4/BH2 ratios of 1–2. Nonetheless, incubation with BH2
was accompanied by an increase in L-[3H]citrulline formation up to
79  11 fmol min1 mg1. In the presence of aminopterin, supple-
mentation of HUVECs with BH2 evoked primarily an increase in
intracellular BH2 and a decrease in L-[3H]citrulline formation down to
basal values.
Our data showing that untreated HUVECs exhibit rather low
BH4 levels and respond to elevation in intracellular BH4 with an
increase in L-[3H]citrulline formation suggest that eNOS is partially
uncoupled under basal conditions. Indeed, incubation of untreated
HUVECs with A23187 triggered an L-NNA-sensitive increase in
dihydroethidium ﬂuorescence that was abolished upon loading the
cells with BH4 (Fig. 5). PAECs, which have 20-fold higher basal
BH4 levels than HUVECs, did not show any eNOS-catalyzed
superoxide formation under these conditions.
3.6. DHFR activity in porcine and human endothelial cells
These results show that PAECs recycle BH2 more efﬁciently
than HUVECs or HMEC-1 cells. To account for the established role
of DHFR in BH4 recycling, we studied kinetics of the enzyme in
endothelial cell cytosols with BH2 and DHF as substrates. As
evident from the data shown in Fig. 6A and Table 3, reduction of
BH2 to BH4 occurred in cytosols of PAECs with a Km of 5.2  1.3 mM
and a Vmax of 0.17  0.03 nmol min1 mg1. Intriguingly, the Vmax
Fig. 5. Basal and A23187-induced ROS formation in PAECs und HUVECs. Cells grown
on glass coverslips were incubated for 4 h in phenol red free culture medium
containing 10 mM dihydroethidium. Where indicated, cells were stimulated with
A23187 (1 mM) and in the absence or the presence of L-NNA (0.3 mM) during the
last hour of incubation. For loading the cells with BH4, BH2 (ﬁnal concentration
0.1 mM) was added to the culture medium 1 h prior to the addition A23187. ROS
formation was quantitated by ﬂuorescence imaging as described in Section 2. Data
are mean values  S.E.M. of 3–5 independent experiments (**p < 0.01, *p < 0.05
compared with untreated control).
Fig. 6. DHFR activity in broken cell preparations. DHFR activity was measured in cell
cytosols or PD10 eluates as described in Section 2 using either BH2 (A) od DHF (B) as
substrate. The data points shown are from experiments with cytosols and are mean
values  S.E.M. of 4–6 cell preparations. The curves shown were obtained by ﬁtting the
mean values to the Michealis–Menten equation. For clarity, results obtained with PD10
eluates (n = 3) are only shown as curve ﬁts without data points.
Fig. 4. Effect of pteridine supplementation on eNOS activity in HMEC-1 cells and
HUVECs. HMEC-1 cells or HUVECs were pretreated for 1 h with culture medium in
the absence or the presence of BH2. Where indicated, aminopterin (ﬁnal
concentration 0.1 mM) was added to the medium 30 min prior to addition of
BH2. Then, cells were washed, and L-arginine to L-citrulline conversion was
determined as described in Section 2. Data are mean values  S.E.M. of 3–5
independent experiments (**p < 0.01, *p < 0.05 compared with untreated control).
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HMEC-1 cells, but the human cells exhibited extremely high Km
values in the range of 0.25–1.5 mM. Virtually identical results were
obtained with cytosols passed over a PD10 column, excluding
competition for BH4 binding by low molecular mass components
present in the cytosolic fractions of the human cells. Also included in
Table 3 are values for the apparent speciﬁcity constant (Vmax/Km),
amounting to (4.3  0.5)  104, (2.22  0.13)  103, and
(5.7  0.6)  102 nmol BH4 min1 mg1 M1, for PAECs, HMEC-1
cells, and HUVECs, respectively. In contrast to the results obtained
with BH2, the Kmvalues for DHF were of the same order of magnitude
(0.3–1.9 mM) in all three cell preparations (Fig. 6B, Table 3).
Aminopterin (0.1 mM) and methotrexate (0.1 mM) completely
inhibited enzyme activity measured with either DHF or BH2 as
substrate (data not shown).
4. Discussion
Our study revealed pronounced differences in BH4 metabolism
in endothelial cells derived from different sources. This particularly
applies to the DHFR-catalyzed regeneration of BH4 from BH2, a
reaction that is considered crucial for cellular BH4 homeostasis
[10–12]. As shown in the present study, PAECs exhibit rather high
levels of BH4 (7 pmol/mg protein) and a BH4/BH2 ratio of 8.4,
which is reduced to 1.5 upon inhibition of DHFR with aminopterin.
In HUVECs and HMEC-1 cells, basal BH4 levels are less than 1 pmol/
mg protein and BH4/BH2 ratios are much lower (1.0 and 0.3 in the
Table 3
Kinetic parameters for DHFR.
BH2 DHF
Km (mM) Vmax (nmol BH4
min1mg1)
Vmax/Km (nmol BH4
min1mg1M1)
Km (mM) Vmax (nmol THF
min1mg1)
PAECs
Cytosol 5.2  1.3 0.17  0.03 4.3  0.5  104 0.4  0.1 2.7  0.5
PD10 eluate 3.2  0.8 0.14  0.04 3.9  0.7  104 0.3  0.1 2.1  0.4
HMEC-1 cells
Cytosol 250 0.6 2.2  0.1  103 1.9  0.6 6.9  0.8
PD10 eluate 250 0.6 3.0  0.4  103 1.1  0.1 6.0  0.2
HUVECs
Cytosol 1500 0.9 5.7  0.6  102 0.3  0.1 1.2  0.2
Km, Vmax, and Vmax/Km values were derived from individual curve ﬁts to the saturation data as described in Section 2 and are mean values  S.E.M. from 3 to 6 experiments each
performed with a different batch of cytosol or eluate. Due to the incomplete saturation curves (see Fig. 6A), only estimates are given for the Km and Vmax values obtained with BH2
and HMEC-1 cells/HUVECs.
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these results conﬁrm that DHFR is essential for BH4 recycling in
cultured cells, the striking differences in the efﬁciency of BH2
reduction in different cell types was unexpected. The highly
efﬁcient BH4 recycling by PAECs as compared to HMEC-1 cells and
HUVECs is unequivocally demonstrated by our observation that
incubation of PAECs with BH2 led to an almost exclusive increase
in intracellular BH4, whereas the human cells, in particular
HUVECs, responded to BH2 supplementation with a rise in both
BH4 and BH2. Nonetheless, incubation with BH2 never elicited a
decrease in the BH4/BH2 ratios, as reported for BAECs [12] and
sEnd.1 cells [5]. While supplementation of PAECs, HMEC-1 cells
and HUVECs with 10 mM BH2 resulted in BH4/BH2 ratios of 19.8,
7.6, and 1.9, respectively (present study), ratios of 1, 0.6 and 0.1
have been reported for BH2-treated murine sEnd.1 cells [5], BAECs
[12] and human aortic endothelial cells [14], respectively.
Although BH4/BH2 ratios may not directly reﬂect DHFR activity,
they appear to be a reliable measure for the efﬁciency of DHFR-
catalyzed BH4 recycling in endothelial cells, the efﬁciency of
which might be ranked as follows: PAECs > HMEC-
1 > HUVECs > sEnd.1 > BAECs > human aortic endothelial cells.
The efﬁcient BH4 recycling by PAECs is most likely a
consequence of the high BH2 afﬁnity of DHFR in these cells
(apparent Km  3 mM). Assuming a cell volume of 1 pl and a
protein content of 100 pg/cell, the data shown in Tables 1 and 2
indicate that the intracellular BH2 concentration of endothelial
cells is in the submicromolar range, suggesting that DHFR is
operating well below its Km-values, which implies that the
apparent speciﬁcity constant (Vmax/Km) is the relevant parameter.
Accordingly, one can estimate hat PAECs are 19 and 75 more
effective than HMEC-1 cells and HUVECs, respectively, in
recovering BH4 from BH2 by DHFR.
What are the consequences of the differences in DHFR kinetics
on endothelial NO formation? PAECs respond to incubation with
BH2 with a marked increase in the BH4/BH2 ratio. Accordingly,
eNOS function in BH4-depleted cells can be restored by supplying
BH4 or BH2. In accordance with literature data showing that the
cellular uptake of BH2 is faster than that of BH4 [28], treatment
with BH2 is even more efﬁcient in restoring eNOS activity than
BH4. When comparing L-citrulline/cGMP data with cellular BH4
levels, it can be seen that in DAHP-treated cells maximal eNOS
activity is regained with 10 mM BH2 (corresponding to 4.3 pmol
BH4/mg) but not with 10 mM BH4 (corresponding to 1.3 pmol
BH4/mg), suggesting that BH4 levels of 2–4 pmol/mg are required
for eNOS coupling. Under basal conditions, BH4 levels are
6.7 pmol/mg and eNOS is saturated with BH4. Accordingly, a
further increase in BH4 as induced by treatment of the cells with
BH4 or BH2 (this study) or the BH4 precursor sepiapterin [29] hasno impact on L-citrulline/cGMP formation. Also, inhibition of DHFR
with aminopterin has no effect, since the resulting BH4/BH2 ratio
and BH4 level and of 5 and 1.5 pmol/mg, respectively, are still
sufﬁciently high for proper eNOS function. However, when these
cells are additionally incubated with BH2, the BH4/BH2 ratio falls
below 1, and eNOS uncoupling occurs.
In contrast to PAECs, HUVECs and HMEC-1 cells exhibit basal
BH4 levels of only 0.3 and 0.7 pmol/mg, respectively. As a
consequence, eNOS is partially uncoupled and L-citrulline forma-
tion rather low. The cells respond to incubation with BH2 with an
increase in BH4 levels and BH4/BH2 ratios, but the effect is less
pronounced than in PAECs. Nonetheless, upon incubation with
10 mM BH2, cellular BH4 levels in HUVECs and HMEC-1 cells are
5.4 and 8.4 pmol/mg, respectively, and thus sufﬁciently high to
promote full eNOS coupling and maximal L-citrulline formation.
These data are in accordance with previous reports showing that
elevation of BH4 levels in HUVECs by sepiapterin is accompanied
by increased eNOS activity measured as formation of L-citrulline
and/or cGMP [30–32].
Despite different efﬁciencies in BH4 regeneration, PAECs,
HUVECs and HMEC-1 cells exhibit sufﬁcient DHFR activity to
respond to supplementation with BH2 with an increase in the BH4/
BH2 ratio and thus no deleterious effect on eNOS occurs. This is not
the case in bovine and murine endothelial cells. Treatment of
BAECs with BH2 (10 mM, 1 h) has been reported to reduce the BH4/
BH2 ratio from 3.8 to 0.6 and to promote a decrease in VEGF-
induced nitrite formation and an increase in H2O2 production [12].
Similarly, a decline in the BH4/BH2 ratio that was accompanied by
an increase in L-NAME-sensitive superoxide production was
observed upon supplementation of sEnd.1 cells with BH2 [5].
Since in both types of cells inhibition of DHFR activity by
methotrexate and/or genetic knockdown of the DHFR protein by
RNA interference has been shown to reduce basal BH4/BH2 ratios
and to increase eNOS-catalyzed ROS formation, DHFR activity in
BAECs and sEnd.1 cells is sufﬁcient to prevent eNOS uncoupling
under basal conditions but not when cells are challenged with BH2
[11,12].
We cannot explain the striking differences in the apparent BH2
afﬁnities of DHFR in different types of endothelial cells. Since
human cells from different sources show pronounced variation in
recycling efﬁciency (see above), our observations are probably not
explained by species differences. The virtually identical results
obtained with desalted cytosols exclude a substrate-competitive
effect of endogenous low molecular mass components of the cells,
but we cannot exclude that an unknown protein present in some
types of cells interferes with BH2 (but not DHF) binding.
Interestingly, the subcellular distribution of DHFR is regulated
by various cellular processes, in particular cell cycle, resulting in
K. Schmidt et al. / Biochemical Pharmacology 90 (2014) 246–253 253partial cytosolic, mitochondrial and nuclear localization of the
protein under certain conditions [33]. The detailed intracellular
distribution of DHFR in the various endothelial cell types is not
known, but it is conceivable that the cellular environment has
subtle effects on protein conformation and substrate binding. For
example, targeting of the enzyme to nuclei requires post-
translational modiﬁcation with the small ubiquitin-like modiﬁer,
SUMO [34,35], a reaction that could affect BH2 binding. In any case,
further work is necessary to settle this issue.
In conclusion, there are pronounced, cell-type speciﬁc
differences in endothelial BH4 regeneration. As a consequence,
basal BH4/BH2 ratios and thus eNOS function vary from cell type
to cell type, and cells respond to extracellular BH2 with either an
increase intracellular BH2 or BH4. Thus, depending on the cell
type, BH2 supplementation may induce or prevent eNOS
uncoupling.
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